MPH HEALTH CARE AG KONV (93M1.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:93M1 - DE000A289V03 - Common Stock
22.9 EUR
+0.3 (+1.33%)
93M1 gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 55 industry peers in the Pharmaceuticals industry. The financial health of 93M1 is average, but there are quite some concerns on its profitability. 93M1 has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
93M1 had negative earnings in the past year.
93M1 had a positive operating cash flow in the past year.
In multiple years 93M1 reported negative net income over the last 5 years.
In multiple years 93M1 reported negative operating cash flow during the last 5 years.
1.2 Ratios
93M1's Return On Assets of -52.66% is on the low side compared to the rest of the industry. 93M1 is outperformed by 81.82% of its industry peers.
93M1 has a Return On Equity of -56.18%. This is in the lower half of the industry: 93M1 underperforms 78.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -52.66% | ||
| ROE | -56.18% | ||
| ROIC | N/A |
ROA(3y)11.46%
ROA(5y)-0.71%
ROE(3y)12.15%
ROE(5y)-0.63%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
93M1's Profit Margin has improved in the last couple of years.
The Profit Margin and Operating Margin and Gross Margin are not available for 93M1 so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y32.91%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
93M1 does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for 93M1 remains at a similar level compared to 1 year ago.
Compared to 5 years ago, 93M1 has about the same amount of shares outstanding.
Compared to 1 year ago, 93M1 has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 5.53 indicates that 93M1 is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 5.53, 93M1 belongs to the best of the industry, outperforming 81.82% of the companies in the same industry.
The Debt to FCF ratio of 93M1 is 5.58, which is a neutral value as it means it would take 93M1, 5.58 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 5.58, 93M1 is in line with its industry, outperforming 49.09% of the companies in the same industry.
A Debt/Equity ratio of 0.02 indicates that 93M1 is not too dependend on debt financing.
93M1 has a better Debt to Equity ratio (0.02) than 89.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 5.58 | ||
| Altman-Z | 5.53 |
ROIC/WACCN/A
WACC7.07%
2.3 Liquidity
A Current Ratio of 0.40 indicates that 93M1 may have some problems paying its short term obligations.
With a Current ratio value of 0.40, 93M1 is not doing good in the industry: 90.91% of the companies in the same industry are doing better.
A Quick Ratio of 0.40 indicates that 93M1 may have some problems paying its short term obligations.
93M1 has a worse Quick ratio (0.40) than 90.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.4 | ||
| Quick Ratio | 0.4 |
3. Growth
3.1 Past
The earnings per share for 93M1 have decreased strongly by -196.45% in the last year.
Measured over the past years, 93M1 shows a very strong growth in Earnings Per Share. The EPS has been growing by 23.67% on average per year.
93M1 shows a strong growth in Revenue. In the last year, the Revenue has grown by 104.72%.
93M1 shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -6.95% yearly.
EPS 1Y (TTM)-196.45%
EPS 3YN/A
EPS 5Y23.67%
EPS Q2Q%-197.62%
Revenue 1Y (TTM)104.72%
Revenue growth 3Y-4.71%
Revenue growth 5Y-6.95%
Sales Q2Q%166.92%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for 93M1. In the last year negative earnings were reported.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, 93M1 is valued a bit more expensive than 61.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 46.69 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 5.45%, 93M1 is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 1.60, 93M1 pays a better dividend. On top of this 93M1 pays more dividend than 94.55% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 1.94, 93M1 pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.45% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DP0%
EPS Next 2YN/A
EPS Next 3YN/A
FRA:93M1 (1/8/2026, 7:00:00 PM)
22.9
+0.3 (+1.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners1.43%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap98.01M
Revenue(TTM)52.00K
Net Income(TTM)-115.23M
Analysts85.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.45% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1884.85 | ||
| P/FCF | 46.69 | ||
| P/OCF | 46.6 | ||
| P/B | 0.48 | ||
| P/tB | 0.48 | ||
| EV/EBITDA | N/A |
EPS(TTM)-26.91
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.49
FCFY2.14%
OCF(TTM)0.49
OCFY2.15%
SpS0.01
BVpS47.93
TBVpS47.93
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -52.66% | ||
| ROE | -56.18% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | 4036.73% |
ROA(3y)11.46%
ROA(5y)-0.71%
ROE(3y)12.15%
ROE(5y)-0.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y32.91%
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 5.58 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.4 | ||
| Quick Ratio | 0.4 | ||
| Altman-Z | 5.53 |
F-Score4
WACC7.07%
ROIC/WACCN/A
Cap/Depr(3y)20.66%
Cap/Depr(5y)19.86%
Cap/Sales(3y)15.7%
Cap/Sales(5y)12.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-196.45%
EPS 3YN/A
EPS 5Y23.67%
EPS Q2Q%-197.62%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)104.72%
Revenue growth 3Y-4.71%
Revenue growth 5Y-6.95%
Sales Q2Q%166.92%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-19.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y40.36%
FCF growth 3YN/A
FCF growth 5Y-24.11%
OCF growth 1Y40.11%
OCF growth 3YN/A
OCF growth 5Y-24.28%
MPH HEALTH CARE AG KONV / 93M1.DE FAQ
Can you provide the ChartMill fundamental rating for MPH HEALTH CARE AG KONV?
ChartMill assigns a fundamental rating of 2 / 10 to 93M1.DE.
What is the valuation status for 93M1 stock?
ChartMill assigns a valuation rating of 0 / 10 to MPH HEALTH CARE AG KONV (93M1.DE). This can be considered as Overvalued.
Can you provide the profitability details for MPH HEALTH CARE AG KONV?
MPH HEALTH CARE AG KONV (93M1.DE) has a profitability rating of 1 / 10.
How financially healthy is MPH HEALTH CARE AG KONV?
The financial health rating of MPH HEALTH CARE AG KONV (93M1.DE) is 4 / 10.
How sustainable is the dividend of MPH HEALTH CARE AG KONV (93M1.DE) stock?
The dividend rating of MPH HEALTH CARE AG KONV (93M1.DE) is 6 / 10 and the dividend payout ratio is 0%.